Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WILLOW CCS
2019-000267-25Phase 4Unknown
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
- Start
- Feb 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of aspirin and rivaroxaban in Chronic Coronary Syndrome (CCS) and coronary arteriosclerosis (3 arms), sponsored by Sheffield Teaching Hospitals NHS Foundation Trust. Primary endpoint: Difference in bleeding time at 2 hours post-dose. Status: unknown.
02
Drugs
aspirinrivaroxaban
03
Conditions
Chronic Coronary Syndrome (CCS)coronary arteriosclerosis
Beyond the preview
Go deeper on 2019-000267-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000267-25.